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SUMMARY 
1. New information identifying nucleotide alterations of human butyrylcholi- 
nesterase allows the use of more specific nomenclature for the variants commonly 
known as atypical, fluoride, silent, and K variant. 
2. In addition to suggesting a system of trivial names and abbreviations, we 
provide a list of formal names that follow the guidelines of the Committee for 
Human Gene Nomenclature. 
3. It is suggested that formal names be included in publications whenever 
possible. 
INTRODUCTION 
There is a need for a systematic nomenclature that reflects new knowledge of the 
structure of human butyrylcholinesterase (BCHE, gene; BChE, protein). Specific 
nucleotide and amino acid alterations in certain genetic variants have recently 
been identified (McGuire et al., 1989; Nogueira et al., 1990). Our proposal for a 
new nomenclature recognizes the need to relate the names contained in over 30 
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years of literature to the new information. Therefore, we propose to use a set of 
trivial names and trivial abbreviations that reflect the old established names, and 
in addition, we provide a list of formal names that follow the guidelines of the 
Committee for Human Gene Nomenclature (Shows et al., 1987; P. J. McAlpine, 
personal communication). 
RECOGNIZED GENETIC VARIANTS 
Nine genetic variants of human serum butyrylcholinesterase are listed in 
Table I. In most cases variants were recognized after patients responded 
abnormally to the muscle relaxant succinylcholine. For example, a person who is 
homozygous for the atypical form of serum butytylcholinesterase experiences 
30 min to 2 hr of muscle paralysis rather than the intended 2 to 3 min after 
receiving a single dose of succinylcholine (Kalow, 1962; Viby-Mogensen, 1983). 
Variants with increased activity are resistant to succinylcholine and may require 
two to three doses to achieve the desired state of paralysis. To date suc- 
cinylcholine is the only drug known to cause abnormal clinical effects in people 
with rare butyrylcholinesterase genetic variants. Two other drugs in the testing 
stages, bambuterol, a prodrug for the bronchodilator drug terbutaline used to 
treat asthma (Tunek and Svensson, 1988), and mivacurium chloride, a new 
muscle relaxant (Savarese et al., 1988), also seem to have variable effects that 
correlate with BCHE genotype. Aspirin, cocaine, and heroin (Lockridge, 1990) 
are hydrolyzed by butyrylcholinesterase, but clinical studies have not been carried 
out to determine whether abnormal responses to these drugs correlate with a rare 
Table L Genetic Variants of Human Serum Butyrylcholinesterase 
Frequency of homozygote 




Atypical 1 : 3500 
Silent 1 : 100,000 
Fluoride 1 : 150,000 
Quantitative Variant J 1 : 150,000 
Quantitative Variant K 1 : 100 
Quantitative Variant H 2 families 
Newfoundland 1 family 
Increased activity 
Cynthiana Variant 4 families 
Johannesburg 1 family 
Whittaker (1986) 
Kalow and Staron (1957) 
Kalow and Gunn (1959) 
Liddell et al. '(1962) 
Harris and Whittaker (1961) 
Garry et aL (1976) 
Evans and Wardell (1984) 
Rubinstein et al. (1978) 
Whittaker and Britten (1988) 
Whittaker and Britten (1987) 
Simpson and Elliott (1981) 
Neitlich (1966) 
Yoshida and Motulsky (1969) 
Delbruck and Henkel (1979) 
Krause et al. (1988) 
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BCHE genetic variant. Whittaker (1986) has reviewed the biochemical properties 
of the rare variants. Table I does not include the C5 variant formerly attributed to 
a second BCHE locus because this second locus codes for a noncholinesterase 
protein (Masson et al., 1990). The C5 variant is not important to the anesthetist. 
PHENOTYPING 
In our laboratory butyrylcholinesterase activity is usually measured by the 
method of Kalow and Lindsay (1955) using benzoylcholine as substrate. Dibu- 
caine number is percentage inhibition of activity in the presence of 10/~M 
dibucaine (Kalow and Genest, 1957). Fluoride number is percentage inhibition of 
activity in the presence of 50/,M sodium fluoride (Harris and Whittaker, 1961). 
RO2 number is percentage inhibition after incubation of the plasma or serum in 
10 -8 M RO2-0683 for 1 hr prior to the addition of substrate (Evans and Wardell, 
1984). RO2-0683 is the dimethylcarbamate of (2-hydroxy-5-phenylbenzyl)- 
trimethyl ammonium. 
The phenotyping method introduced by Kalow and Genest (1957), based on  
dibucaine number, is an excellent and reliable method for determining whether a 
person has atypical cholinesterase. The atypical allele can be detected in 
homozygotes as well as in heterozygotes. This is a very special feature of atypical 
BChE, since most of the other variants cannot be identified when they occur in 
combination with the usual allele. It is therefore difficult or impossible to tell by 
phenotyping tests whether a person is a carrier of the silent, fluoride, H, J, K, or 
Newfoundland variant unless the family also has the atypical variant and enough 
members of a family are tested to determine the pattern of inheritance. 
GENOTYPING 
The new methods of gene amplification by the polymerase chain reaction 
(PCR) followed by DNA sequencing (McGuire et al., 1989; Nogueira et al., 1990) 
and PCR followed by probing with a biotinylated oligonucleotide (La Du et al., 
Table II. Nomenclature for Homozygous Forms of Human Butyrylcholinesterase Variants a 
Common Phenotypic Amino acid DNA Formal 
name description alteration alteration name for genotype 
Usual Normal None None BCHE 
Atypical Dibucaine nt 209 (GAT to GGT) BCHE* 70G 
resistant 70 Asp ~ Gly 
Silent-1 Silent, no nt 351 (GGT to GGAG) BCHE*FS117 
activity 117 Gly---> Frameshift 
Fluoride-1 Fluoride nt 728 (ACG to ATG) BCHE*243M 
resistant 243 Thr--~ Met 
Fluoride-2 Fluoride nt 1169 (GGT to GTF) BCHE*390V 
resistant 390 Gly---~ Val 
K variant K poly- nt 1615 (GCA to ACA) BCHE*539T 
morphism 539 A l a ~  Thr 
a Amino acid 1 as well as codon 1 is the N terminal of the mature protein. 
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1990) have allowed identification of the nucleotide alterations in the variants of 
BCHE. DNA sequencing overcomes the limitations of phenotyping, because all 
variants can be precisely identified. Furthermore the new methods discriminate 
among similar phenotypes, such as fluoride-1 and fluoride-2. Tables II and III list 
the variants identified in our laboratory by DNA sequencing. Figures showing the 
location of nucleotide and amino acid substitutions within the complete sequence 
of human BChE have been published (Arpagaus et al., 1990; Lockridge, 1990). A 
limitation of DNA sequencing is that it is slow compared to phenotyping, 
requiring 1 week rather than 30 min to analyze one person. 
/ 
ATYPICAL 
All atypicals sequenced to date have a substitution at nucleotide 209, 
changing A to G and changing codon 70 from aspartic acid to glycine (McGuire et 
al., 1989). The number of unrelated atypical alleles we have sequenced is 20. 
Atypical BChE has the kinetic properties of an enzyme that has a deficient 
anionic site. Atypical BChE has a reduced affinity for neutral substrates and a 
normal turnover number, kca t (Lockridge and La Du 1978). Therefore, Asp 70 
appears to be an essential component of the anionic site. 
A second substitution was found in greater than 90% of atypical genes. The 
second substitution was at nucleotide 1615, where G was replaced by A and 
codon 539 was changed from alanine to threonine. Since some atypicals lack this 
second substitution we conclude that the atypical phenotype is due to the 
substitution of Asp 70 by Gly (McGuire et al., 1989). The 539 Ala---~Thr 
mutation represents the K variant. Thus, a single BCHE chromosomal strand 
may carry two mutations: the mutation responsible for the atypical phenotype 
and a mutation responsible for the K variant phenotype. This linkage disequi- 
librium would be expected if a founder were responsible for the atypical genes, 
and his atypical mutation occurred on a chromosomal strand carrying the K 
mutation. The disequilibrium with the K v.ariant mutation may well explain why 
there are about one-third less atypical than usual BChE molecules per ml of 
serum (Eckerson et al., 1983). 
K VARIANT 
The K variant, named in honor of Werner Kalow, is associated with a 33% 
reduction in serum BChE activity (Rubinstein et al., 1978). By sequencing the 
DNA of family members and by pedigree analysis, we found that the K 
phenotype was associated with a single nucleotide substitution at nucleotide 1615, 
which changed codon 539 from alanine to threonine (Bartels et al., 1989). Our 
conclusion that this substitution explained the K variant was supported by the 
observation that the frequency of the 539 Ala---~ Thr mutation was equivalent to 
the 1% frequency of the homozygote K variant (Evans and Wardell, 1984; 
Whittaker and Britten, 1985). Though the K variant is the most common 
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mutation of BChE, its clinical importance has been noted only when it is present 
in association with atypical BChE. 
FLUORIDE 
The fluoride phenotype is resistant to the inhibitor NaF. Two mutations 
causing the fluoride phenotype have been found so far. One family had a 
substitution at nucleotide 728 of C to G, changing codon 243 from Thr to Met, 
while three families had a substitution at nucleotide 1169 of G to T, changing 
codon 390 from Gly to Val. The first fluoride mutation identified by DNA 
sequencing is fluoride-I, the second is fluoride-2, etc. 
SILENT 
The silent phenotype is characterized by zero BChE activity or very low 
activity, less than 2% of normal (Rubinstein et al., 1970). We have identified one 
type of silent mutation called silent-1 or silent-Ann Arbor (Nogueira et al., 1990). 
The mutation in Table II was found in two unrelated families, one Italian- 
American and one Persian. This is a complex mutation in which the T at 
nucleotide 351 was replaced by two nucleotides, AG. The frameshift caused a 
stop codon to appear at codon 129 so that protein synthesis was prematurely 
terminated. Only a truncated BChE, about 22% of the length of the usual 
enzyme, could be produced. It lacked the active site serine at position 198 and 
therefore had no activity. The serum from this silent phenotype did not 
cross-react with antibody to human serum BChE and had zero activity with 
benzoylcholine and alpha-naphthylacetate. Another serum with the silent phe- 
notype also had zero BChE activity and no cross-reactive material but did not 
contain the above mutation. Therefore a silent-2 is likely to exist. 
NOMENCLATURE 
Trivial Names  A modification of the trivial names for the genetic variants 
has already been suggested above. A number following the trivial name, for 
example, fluoride-I, fluoride-2, can be used to indicate that the fluoride 
phenotype includes several different nucleotide alterations (Table II). Following a 
practice established for the hemoglobin variants, a geographic name can be used 
as a trivial name. The geographic name can be appended to an already existing 
trivial name, as in silent-Ann Arbor, or can be used alone as in variants 
Newfoundland, Cynthiana, and Johannesburg. 
In daily laboratory work it is our practice to use the simplest names possible. 
A system of two-letter abbreviations is well established but fails to describe the 
fact that most atypicals contain two mutations. Therefore, we propose a system of 
two-, three-, and four-letter abbreviations in Table III. A two-letter abbreviation 
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is used for a genotype having one mutation per DNA strand, for example, SS for 
homozygous silent. Three- and four-letter abbreviations are used when one or 
both alleles contain a double mutation. The double mutation on a single DNA 
strand of atypicals is represented by two letters, AK. If only one strand has a 
double mutation while the second strand has a single mutation, the abbreviation 
contains three letters, for example, AK/K. The genotype abbreviation for a 
double mutation on both alleles is AK/AK with a slash separating the two alleles. 
This system of trivial abbreviations does not distinguish between fluoride-1 and 
fluoride-2, both being refferred to as F, but numbers could be added if this 
distinction becomes necessary. 
Formal Names. The Human Gene Mapping Nomenclature Committee has 
designated B C H E  as the gene symbol for butyrylcholinesterase (P. J. McAlpine, 
personal communication). B C H E  now replaces CHE1, the former symbol. 
BCHEL1 and B C H E L 2  are the butyrylcholinesterase-like sites to which the 
cDNA probe hybridizes (Soreq et al., 1987; Zakut et al., 1989). Italics represent 
genotype, while standard type represents phenotype. An asterisk separates the 
symbols for gene and allele, and the single-letter amino acid symbol is used to 
identify mutations (Shows et al., 1987). In the example BCHE*7OG, the 70th 
amino acid from the N terminal of the mature protein has a substitution of glycine 
for aspartate (70 Asp ~ Gly). A slash separates alleles and indicates chromosome 
homologues. Frameshift is indicated by FS. In the example BCHE*70G539T/ 
BCHE*F117, one allele has a double mutation (70 Asp---~Gly and 539 Ala---~ 
Thr), while the second allele has a frameshift mutation at codon 117. See Table 
III. 
The gene symbol for human acetylcholinesterase has been designated 
ACHE.  Drosophila, nematode, and mouse geneticists use Ace as the symbol for 
the ACHE gene. However, Ace cannot be used for human acetylcholinesterase 
because all letters are not capitalized. A C E  is not available as a gene symbol for 
human acetylcholinesterase because it has been assigned to a different human 
gene. 
The gene symbol for the C5 phenotype will remain CHE2 until the C5 
phenotype is better understood (P. J. McAlpine, personal communication). 
ONE FUNCTIONAL BUTYRLCHOLINESTERASE GENE 
There is general agreement that the rare genetic variants, atypical, fluoride, 
and silent, are allelic with the usual form of BChE. Linkage analysis showed that 
BChE was closely linked to human transferrin (Robson et al., 1966; Sparkes et 
al., 1984). When Yang et al., (1984) mapped transferrin to human chromosome 3 
in the long arm q21-25, it was clear that BCHE also mapped in this region. The 
in situ hybridization studies of Soreq et al., (1987) with a human BCHE cDNA 
probe confirmed that chromosome 3q21-26 was the location of a human BCHE 
gene. 
The idea that two loci may code for human BChE originated in the work of 
Harris et al., (1963), who reported that an extra, slow-migrating component, C5, 
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was inherited independently of the atypical variant. It was unclear whether C5 
represented a second BCHE gene or represented a noncholinesterase protein. It 
became common to refer to two BCHE loci and to lose sight of the possibility 
that the second locus could be coding for a modifying protein that was not BChE, 
although Scott and Powers (1974) concluded that C5 was a hybrid between BChE 
and a second protein, whose identity was unknown. The chromosomal location of 
C5, whose gene symbol is CHE2, was tentatively identified by Lovrien et  al. 
(1978) as chromosome 16 based on a weak linkage with Hp and a lod score of 2.3. 
Marazita et al. (1989) also showed a weak linkage of CHE2 and haptoglobin on 
chromosome 16, with a lod score of 2.5. A lod score less than 3.0 is considered 
statistically insignificant and therefore both Lovrien et al. (1978) and Marazita et 
al. (1989) were cautious in assigning CHE2 to chromosome 16. A much stronger 
lod score of 4.2 was obtained by Eiberg et al. (1989) for the linkage between 
y-crystallin gene cluster, CRYG, and CHE2, thus mapping CHE2 to chromo- 
some 2 bands q33-q35. Eiberg's result that CHE2 mapped to chromosome 2 did 
not, by itself, rule out the possibility that CHE2 represented a second BCHE 
locus. This interpretation can, however, be made from the data of Soreq et al. 
(1987) and Zakut et al. (1989), who showed no hybridization of BCHE cDNA to 
chromosome 2. 
Additional evidence supporting the interpretation that the BChE component 
of C5 originates from the same BCHE locus as the major BChE enzyme comes 
from the work of Arpagaus et al. (1990) and Masson et  al. (1990). Arpagaus et al. 
(1990) isolated the B C H E  gene and reported that the human genome contains a 
single copy of the BCHE gene. This conclusion can be challenged with the 
argument that Arpagaus et  al. examined DNA from three individuals and would 
therefore have missed a second BCHE gene that existed in only a small 
percentage of the population. Masson et al. (1990) examined the possibility that a 
small percentage of the population might carry two BCHE genes. The most likely 
section of the population that might carry a second gene was the group that 
carried the C5 component, a group that includes 10% of Caucasians (Robson and 
Harris, 1966). Therefore, Masson et  al. (1990) prepared Southern blots from total 
genomic DNA isolated from three people with the C5 phenotype. Hybridization 
results revealed that people with the C5 phenotype had a single copy of the 
BCHE gene and that this BCHE gene was indistinguishable from the BCHE gene 
that is present in people lacking C5. The argument that can be raised against this 
conclusion is that hybridization conditions were too stringent to detect a second 
BCHE locus that might be less than 70% identical with the major BCHE locus. 
The interpretation we favor is that C5 is a hybrid protein encoded by the 
BCHE gene on chromosome 3 bands q21-q26 and an unidentified gene on 
chromosome 2. A recent example of the ability of serum BChE to combine with a 
foreign protein comes from the work of Masson (1989), who found that the 
electrophoretic band termed C2 is a disulfide-linked complex between one BChE 
subunit and one albumin molecule. An alternative interpretation for C5 was 
presented by Soreq et  al. (1987), who suggested that CHE2 codes for a protein 
which is similar to that encoded by the BCHE locus and that CHE2 maps to 
chromosome 16. 
BChE Nomenclature 87 
The question of the number of BCHE genes is very important to the Human 
Genome Mapping and Sequencing project. Single-copy DNA sequences (that 
occur only once in the genome) that can be easily recovered by PCR are 
proposed as the landmarks that define position on the physical map (Olson et al., 
1989). In our view BCHE can be one of these sequence-tagged sites (STS) for the 
long arm of chromosome 3. To date we have recovered BCHE sequences by PCR 
from total genomic DNA of approximately 100 individuals with results that are 
completely consistent with the existence of a single functional BCHE gene. 
Though BCHE cDNA hybridized to two regions on chromosome 3 (Zakut et al., 
1989) and one region on chromosome 16 (Soreq et al., 1987; Zakut et al., 1989), 
these additional regions do not interfere with amplification of the BCHE gene by 
PCR. 
The possibility exists that the additional loci that hybridize to BCHE cDNA 
(Soreq et al., 1987; Zakut et al., 1989) are genes homologous to the major form 
of BCHE. The homology might be too low to allow hybridization to PCR 
oligonucleotides, and too low to hybridize to cDNA on Southern blots, but high 
enough to be responsive to the conditions used in hybridization to chromosomes. 
If this is the case, then the question becomes one of definition as to what 
percentage homology classifies a gene as BCHE. This question was raised at the 
third CHE meeting, where it was concluded that sequence information from 
many more animals was needed before it would be clear what distinguished 
butyrylcholinesterase from several related esterases including acetylcholinesterase 
and carboxylesterases. 
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